


Journal Pre-proof

ResTORing barrier function in the skin

Jocelyn Wang, PhD, Mark H. Kaplan, PhD, Kai Yang, PhD



PII: S0091-6749(19)31328-4

DOI: <https://doi.org/10.1016/j.jaci.2019.10.007>

Reference: YMAI 14221

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 27 August 2019

Revised Date: 5 October 2019

Accepted Date: 11 October 2019

Please cite this article as: Wang J, Kaplan MH, Yang K, ResTORing barrier function in the skin, *Journal of Allergy and Clinical Immunology* (2019), doi: <https://doi.org/10.1016/j.jaci.2019.10.007>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

1 **ResTORing barrier function in the skin**

2
3 Jocelyn Wang¹, PhD, Mark H. Kaplan^{1,2}, PhD, Kai Yang, PhD^{1,2}

4
5 ¹ Department of Pediatrics and Herman B Wells Center for Pediatric Research
6 Indiana University School of Medicine, Indianapolis, IN 46202

7 ² Department of Microbiology and Immunology, Indiana University School of Medicine,
8 Indianapolis, IN, 46202

9
10 Correspondence:

11 Mark H. Kaplan

12 Indiana University School of Medicine

13 1044 West Walnut St. Room 202, Indianapolis, IN 46202

14 Office: 317.278.3696

15 mkaplan2@iu.edu

16
17 Footnotes:

18 The authors have no financial conflicts of interest.

19 Preparation of this editorial was supported by a PHS grant from the National Institutes
20 of Health R01 AI095282. Support provided by the Herman B Wells Center was in part
21 from the Riley Children's Foundation.

22
23 Key Words: mTORC2, atopic dermatitis, barrier function; lipid biosynthesis

24
25

26 The primary functions of the epidermis include water retention, thermal and pH
27 homeostasis, and protecting against the entry of pathogenic microbes or toxic
28 substances into the body^{1,2}. Appropriate epidermal barrier formation relies on the
29 progressive differentiation of keratinocytes from the proliferating cells within the basal
30 cell layer to the terminally differentiated cornified layer or stratum corneum². The
31 stratum corneum is composed of keratin macrofibrils and crosslinked cornified
32 envelopes encased in lipid bilayers. Filaggrin and lipids produced by epidermal granular
33 cells control the assembly of a lipid-keratin matrix in forming this semi-permeable barrier.
34 Defects in the integrity of the epidermal barrier may result in a variety of inflammatory
35 skin disorders including atopic dermatitis (AD) and ichthyosis.

36
37 Ichthyosis is characterized by the presence of excessive amounts of dry, scaly, and
38 thick skin surface. The etiology of the ichthyosis is attributed to the complex interplay
39 between keratinocyte differentiation and metabolic dysregulation. Genetic and clinical
40 evidence indicates that defective expression and function of genes involved in the
41 filaggrin processing and lipid synthesis impair the epidermal barrier acquisition and drive
42 the onset of ichthyosis¹, resulting in water loss, entry of infectious microbes, and
43 infiltration of inflammatory lymphocytes. From the developmental perspective, it has
44 been proposed that balancing keratinocyte proliferation and differentiation is crucial for
45 shaping the epidermal barrier formation and function. Yet how keratinocytes coordinate
46 their differentiation and lipid metabolism in the formation and maintenance of epidermal
47 barrier remains elusive.

48
49 As with most allergic diseases, AD is a multifactorial disease, and genetics plays a
50 significant role in disease progression. Because AD is a T helper 2-biased disease,
51 many predisposing genes are linked to immune responses^{3,4}. Recent studies have also
52 identified the critical role of fatty acids synthesis in epidermal barrier formation and
53 homeostasis^{5,6}. One of the best-known risk factor genes, the filaggrin (*FLG*) gene,
54 encodes an epidermal differentiation protein that is critical in forming the lipid-keratin
55 matrix and epidermal integrity^{3,4}. Mutations in the *FLG* gene can cause ichthyosis
56 vulgaris and are a strong risk factor for AD^{3,4}. However, *FLG* mutations do not account
57 for all AD cases, and not every carrier of a *FLG* mutation develops AD. Therefore, the
58 underlying molecular mechanisms that regulate epidermal barrier function remain
59 incompletely defined.

60
61 The mechanistic target of rapamycin (mTOR) is an evolutionally conserved serine-
62 threonine kinase that functions via two multiprotein complexes⁷, namely mTORC1 and
63 mTORC2, characterized by the obligate proteins Raptor and Rictor, respectively. As a
64 central node in cellular metabolism and cell growth, these mTOR complexes dictate the
65 cell fate decision and function of a variety of cells through coupling proliferation and
66 differentiation in response to microenvironmental cues. In contrast to extensive studies
67 of mTOR complexes in T cells⁸, it is only now beginning to be understood how mTOR
68 signaling regulates the epidermal barrier formation. Recent studies reveal that mTORC1
69 is crucial for keratinocyte proliferation and the early epidermal differentiation program⁹.
70 In this issue of Journal of Allergy and Clinical Immunology, Ding et al show that

71 mTORC2 signaling controls the terminal differentiation and function of keratinocytes in
72 the late stage of epidermal barrier formation (Figure 1)¹⁰.

73
74 Previous studies by Ding et al demonstrated that mTOR signaling is indispensable for
75 the epidermal barrier formation⁹, albeit with differential roles defined for mTORC1 and
76 mTORC2. By crossing mice carrying loxP-flanked target alleles (*Mtor*^{fl/fl}, *Rptor*^{fl/fl} or
77 *Rictor*^{fl/fl}) with human keratin 14 (K14) Cre recombinase transgenic mice, Ding et al were
78 able to respectively abolish complete mTOR signaling, mTORC1 activation, or
79 mTORC2 activation specifically in the epidermis⁹. Deletion of *Mtor* in mouse epidermis
80 (mTOR^{EKO}) resulted in newborns with defective epidermal barrier function that succumb
81 to death shortly after birth⁹. They also demonstrated that mTORC1 and mTORC2 have
82 distinct functions in maintaining healthy epidermal differentiation and formation.
83 Newborn mice without Raptor displayed a similar phenotype with the mTOR^{EKO} mice.
84 However, mice with deletion of Rictor in the epidermis (*Ric*^{EKO}) were able to survive
85 despite abnormal skin development⁹. In the current study, Ding et al follow up on their
86 initial findings with more detailed experiments investigating the precise mechanism by
87 which mTORC2 regulates epidermal barrier formation¹⁰.

88
89 Using *Ric*^{EKO} mice, Ding et al demonstrate that disruption of mTORC2 function alters
90 normal epidermal formation. *Ric*^{EKO} mice develop an ichthyosis-like phenotype at birth
91 with reduced epidermal thickness and enhanced trans-epidermal water loss, which is
92 similar to what is observed in human patients⁴. By RNA-sequencing of epidermis from
93 wild type and *Ric*^{EKO} E19.5 embryos, they reveal that many genes involved in
94 keratinization, wound repair and keratinocyte differentiation are upregulated in the
95 mutants, while immune regulating and lipid metabolism genes are downregulated.
96 These findings suggest that dysfunctional mTORC2 promotes compensatory repair
97 pathways and that lipid metabolism might be critical in epidermal formation.


98
99 To begin to address the role of lipid metabolism in regulating epidermal development,
100 Ding et al¹⁰ measure the lipid content in epidermis and show that there are decreased,
101 and that there are altered lipid contents in several layers of epidermis. Furthermore,
102 they show that mice with Rictor-deficient epidermis have altered proteolytic activity
103 resulting in lower amounts of filaggrin monomers despite comparable levels of filaggrin
104 mRNA and profilaggrin protein with controls. A direct link between mTORC2 function
105 and filaggrin processing is established through complementation of the fillagrin
106 processing defect in *Ric*^{EKO} primary keratinocyte culture following Akt-Ser473
107 phosphorylation. *Ric*^{EKO} mice also demonstrated altered immune cell profiles, including
108 more CD4⁺ T cell and fewer $\gamma\delta$ T cells in their epidermis. With defective mTORC2
109 function and inappropriate immune cell compositions, *Ric*^{EKO} mice respond poorly to the
110 hapten DNFB. They also upregulate stress and proinflammatory genes in their ear skin
111 in response to DNFB.

112
113 Collectively, Ding et al¹⁰ demonstrate a distinctive role of mTORC2 in regulating intact
114 skin barrier function. The animal model they chose parallels several hallmarks in human
115 AD patients, including altered skin morphology and disrupted immune cell compositions,
116 which suggest that their findings can be potentially translated to human studies. Among

117 the two complexes of mTOR, mTORC1 has been studied more extensively due to its
118 responsiveness to acute treatment of rapamycin⁷. However, more and more effort has
119 been devoted to investigating the importance of mTORC2 in cellular regulation and
120 disease progression. Ding et al¹⁰ conduct the first study to demonstrate that mTORC2
121 enforces the AKT-dependent filaggrin processing and orchestrates de novo lipid
122 synthesis in keratinocytes. These processes shape the immune cell composition in the
123 skin at steady state and its immune responses to allergens. These results indicate that
124 dysfunctional mTORC2 could be another risk factor for skin diseases. Hence, carriers of
125 mutations in mTORC2 could have higher risk of developing skin diseases. Certain
126 cancer treatments also inhibit mTOR activities, which might compromise patients' skin
127 integrity⁷. Combined therapy should be designed carefully to manage this potential side
128 effect. Further studies are warranted to examine how mTORC2-dependent signaling
129 regulates lipid metabolism. Moreover, the relevant ligands that activate mTORC2-
130 dependent signaling have not been defined, and whether other environmental signals
131 such as the epidermal microbiome, detergents, or particulate matter and pollution play a
132 role in activating mTOR has not been tested. mTORC2 regulates many interacting
133 pathways that are druggable and could serve as potentially novel therapeutic targets to
134 reestablish epidermal barrier integrity and improve the treatment for common skin
135 disorders⁷. Hence, identifying the roles of mTORC2-regulated metabolic networks in
136 skin disease development has become the next pressing question.

- 137
138
- 139 1. Segre, J.A. **Epidermal barrier formation and recovery in skin disorders.** *J Clin*
140 *Invest.* 2006;116:1150-1158.
 - 141 2. Natsuga, K. **Epidermal barriers.** *Cold Spring Harb Perspect Med.*
142 2014;4:a018218.
 - 143 3. Kubo, A., Nagao, K., Amagai, M. **Epidermal barrier dysfunction and cutaneous**
144 **sensitization in atopic diseases.** *J Clin Invest.* 2012;122:440-447.
 - 145 4. Weidinger, S., Novak, N. **Atopic dermatitis.** *Lancet.* 2016;387:1109-1122.
 - 146 5. Aldahmesh, M.A., Mohamed, J.Y., Alkuraya, H.S., Verma, I.C., Puri, R.D., Alaiya,
147 A.A., et al. **Recessive mutations in ELOVL4 cause ichthyosis, intellectual**
148 **disability, and spastic quadriplegia.** *Am J Hum Genet.* 2011;89:745-750.
 - 149 6. Ilic, D., Bollinger, J.M., Gelb, M., Mauro, T.M. **SPLA2 and the epidermal barrier.**
150 *Biochim Biophys Acta - Mol Cell Biol Lipids.* 2014;1841:416-421.
 - 151 7. Saxton, R.A., Sabatini, D.M. **mTOR Signaling in Growth, Metabolism, and**
152 **Disease.** *Cell.* 2017;168:960-976.
 - 153 8. Chapman, N.M., Boothby, M.R., Chi, H. **Metabolic coordination of T cell**
154 **quiescence and activation.** *Nat Rev Immunol.* August 2019:Epub ahead of print.
 - 155 9. Ding, X., Bloch, W., Iden, S., Rüegg, M.A., Hall, M.N., Leptin, M., et al. **mTORC1**
156 **and mTORC2 regulate skin morphogenesis and epidermal barrier formation.**
157 *Nat Commun.* 2016;7:13226.
 - 158 10. Ding, X., Willenborg, S., Bloch, W., Wickström, S.A., Wagle, P., Brodesser, S., et
159 al. **Epidermal mTORC2 controls lipid synthesis and filaggrin processing in**
160 **epidermal barrier formation.** *J Allergy Clin Immunol.* 2019;this issue.
- 161

Microbiota, particulate matter, pollution, detergents, other environmental agents



Journal